Demand for Alpha Emitters for Use In Ovarian Cancer Medical Applications Is Predicted To Rise Rapidly at a CAGR of 22% by 2032

According to the alpha emitters market report by Fact.MR, a market research and competitive intelligence provider, the global market is valued at US$ 1 billion in 2022 and is expected to surge ahead at an astounding CAGR of 21% to reach US$ 6.7 billion by the end of 2032.

Download Free Sample Copy of This Report:

https://www.factmr.com/connectus/sample?flag=S&rep_id=7810

Demand for alpha emitters for use in ovarian cancer medical applications is predicted to rise rapidly at a CAGR of 22% from 2022 to 2032. This can be primarily attributed to the rise in ovarian cancer cases across the world.

Competitive Landscape

• Ovarian cancer is the fifth most prevalent cancer-related cause of death among women in the United States, according to the American Cancer Society. The American Cancer Society predicts that 19,880 women will be newly diagnosed with ovarian cancer in the U.S. in 2022. Ovarian cancer will claim the lives of approximately 12,810 women.

The main market participants are concentrating on creating cutting-edge radionuclides for the treatment of various forms of ovarian cancer.
For example,

• January 2021: Soricimed Biopharma Inc. and Orano Med decided to concentrate on the creation of an advancedPeptide Receptor Radionuclide Therapy to treat solid tumour cancers.

Share Your Requirements & Get Customized Reports:

https://www.factmr.com/connectus/sample?flag=RC&rep_id=7810

Key Companies Profiled:

• Actinium Pharmaceuticals, Inc.
• Alpha Tau Medical
• Bayer AG
• Fusion Pharma
• IBA Group
• IBA Radiopharma Solutions
• Lantheus Medical Imaging, Inc.
• NTP Radiosotopes SOC Ltd.
• RadioMedix, Inc.
• Siemens Healthineers

"High Demand for Alpha Emitters from Nuclear Medicine & Radiopharmaceutical Applications"

The demand for alpha emitters from nuclear medicine and radiopharmaceutical applications is growing rapidly. Alpha emitters are used in a variety of medical applications, including cancer diagnosis and treatment, imaging, and radiotherapy. Alpha emitters are also used in research and development of new radiopharmaceuticals.

The increasing demand for alpha emitters is driven by the growing need for more accurate and precise diagnosis and treatment of diseases, as well as the development of new radiopharmaceuticals. Additionally, the increasing use of nuclear medicine in developing countries is also contributing to the growth in demand for alpha emitters.

Full Access to this Report Is Available:

https://www.factmr.com/checkout/7810

Key Segments:

• By Type of Radionuclide:

o Radium
o Lead
o Bismuth
o Actinium

• By Application:

o Bone Metastasis
o Ovarian Cancer
o Pancreatic Cancer
o Melanoma
o Lymphoma

• By Region:

o North America
o Latin America
o Europe
o East Asia
o South Asia & Oceania
o MEA

Questionnaire answered in the report include:

• How the industry has grown?
• What is the present and future outlook on the basis of region?
• What are the challenges and opportunities?
• Why the consumption in region?
• In which year segment is expected to overtake segment?

Explore Fact.MR's More Insights on the Healthcare Domain

Skincare Device Market: https://www.prnewswire.com/news-releases/sales-of-skincare-devices-to-surpass-uss-43-48-bn-as-prevalence-of-dermatological-diseases-increases-factmr-report-301506974.html

ENT Medical Devices Market: https://www.prnewswire.com/news-releases/ear-nose-throat-ent-medical-devices-manufacturers-target-applications-in-cataract--glaucoma-treatment-factmr-301262063.html

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of industry research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.